Log in
E-mail
Password
Show password
Remember
Forgot password ?
Become a member for free
Sign up
Sign up
New member
Sign up for FREE
New customer
Discover our services
Settings
Settings
Dynamic quotes 
OFFON

REDHILL BIOPHARMA LTD.

(RDHL)
  Report
SummaryQuotesChartsNewsRatingsCalendarCompanyFinancialsConsensusRevisions 
SummaryMost relevantAll NewsAnalyst Reco.Other languagesPress ReleasesOfficial PublicationsSector news

Redhill Biopharma, AstraZeneca, Nektar Therapeutics Settle Movantik Patent Litigation with Aurobindo

09/23/2021 | 10:06am EDT


ę MT Newswires 2021
All news about REDHILL BIOPHARMA LTD.
10/12REDHILL BIOPHARMA : Obtains US Patent for H. Pylori Treatment Through 2034
MT
10/12REDHILL BIOPHARMA : Announces New U.S. Patent Covering - Form 6-K
PU
10/12RedHill Biopharma Ltd. Provides Earnings Guidance for the Quarter Ended September 30, 2..
CI
10/07PRESS RELEASE : Heidelberg Pharma AG: Interim -2-
DJ
10/06REDHILL BIOPHARMA : Bacterial Infection Drug Talicia Added to California's Medicaid Progra..
MT
10/06REDHILL BIOPHARMA : Designed as a first-line option to address the high resistance of H. p..
PU
10/06Redhill Biopharma's Talicia« Added to Medi-Cal Contract Drug List with No Prior Authori..
CI
10/04ADRs Close Lower; RedHill Biopharma Rises
DJ
10/04REDHILL BIOPHARMA : Shares Rise as New Data Shows Potential in COVID-19 Drug Candidate
MT
10/04REDHILL BIOPHARMA : A median four days earlier hospital discharge for opaganib-treated pat..
PU
More news
Analyst Recommendations on REDHILL BIOPHARMA LTD.
More recommendations
Financials (USD)
Sales 2021 92,3 M - -
Net income 2021 -92,1 M - -
Net Debt 2021 - - -
P/E ratio 2021 -5,05x
Yield 2021 -
Capitalization 228 M 228 M -
Capi. / Sales 2021 2,47x
Capi. / Sales 2022 1,58x
Nbr of Employees 182
Free-Float 71,8%
Chart REDHILL BIOPHARMA LTD.
Duration : Period :
RedHill Biopharma Ltd. Technical Analysis Chart | RDHL | US7574681034 | MarketScreener
Technical analysis trends REDHILL BIOPHARMA LTD.
Short TermMid-TermLong Term
TrendsBearishBearishBearish
Income Statement Evolution
Consensus
Sell
Buy
Mean consensus BUY
Number of Analysts 7
Last Close Price 4,89 $
Average target price 18,79 $
Spread / Average Target 284%
EPS Revisions
Managers and Directors
Dror Ben-Asher Chairman & Chief Executive Officer
Micha Ben-Chorin Chief Financial Officer
Reza Fathi Senior Vice President-Research & Development
Ira N. Kalfus Medical Director
June Sherie Almenoff Chief Medical Officer
Sector and Competitors
1st jan.Capi. (M$)
REDHILL BIOPHARMA LTD.-39.48%228
GILEAD SCIENCES, INC.16.08%84 795
WUXI APPTEC CO., LTD.29.45%66 184
BIONTECH SE203.83%59 820
REGENERON PHARMACEUTICALS14.52%57 519
VERTEX PHARMACEUTICALS-23.09%47 156